The national insurers’ financial performance in Q2 2025: A tale of two (types of) payers
Explore the national insurers' financial performance in Q2 2025, including the major moves they've made to address profitability challenges, and what we’re watching moving forward.
At a glance
Read on to get our full commentary, or use the links below to jump to a specific area of interest:
-
The national insurers’ financial performance in Q2 2025 was hurt…
-
Rising MLRs attributed to elevated medical costs—especially for government payers
-
Is AI the answer to insurers’ woes? Insurers appear to…
-
Deep dives on the national insurers
-
What we’re watching
-
Parting thoughts: The national insurers’ financial performance in Q2 2025
Over the course of the past few weeks, all five of the large, publicly traded health plans have hosted their second set of earnings calls for the year, sharing their performance from Q2 and their outlook for the remainder of 2025. We make it a point to stay on top of the performance of these players not only to keep track of the financial prospects of the overall health insurance industry, but also because they offer a telling window into ongoing demographic shifts, the margin outlook for providers, the real-world/cost implications of innovations from the drug pipeline, and the state of the regulatory environment. You can find our analysis of the “Big Five” national insurers’ financial performance in Q1 in our recent blog post, linked below.
Missed our post on the national insurers’ financial performance in Q1? Catch up by clicking here.

Union Healthcare Insight
Log in to continue reading
Not a member yet? Create a free account for limited access.
Related insights
The Great Utilization Shift
For-profit health systems’ financial performance in 2025—and what to expect in 2026
The national insurers’ financial performance in Q4 2025: How the Big Five insurers weathered 2025—and what to expect in 2026